Race Oncology Limited (RAC.XA)

1.3793 -0.0657 (-4.55%) At close: 03:59PM AEST

Race Oncology Limited

Gateway, 1 Macquarie Place
Level 36
Sydney, NSW 2000
Australia
61 2 8051 3043
https://www.raceoncology.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Daniel Tillett	Chief Executive Officer	613.16k	N/A	N/A
Dr. Peter M. Smith Ph.D.	Executive Director	635	N/A	1963
Ms. Christina Manfre	Chief Financial Officer	N/A	N/A	N/A
Prof. Tim Hammond	Interim Chief Scientific Officer	N/A	N/A	N/A
Dr. Michelle Rashford	Chief Medical Officer	N/A	N/A	N/A
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.	Company Secretary	N/A	N/A	1963

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Corporate governance

Race Oncology Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.